+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Carglumic Acid Market by Application, Distribution Channel, End User, Product Type, Age Group - Global Forecast to 2030- Product Image
Carglumic Acid Market by Application, Distribution Channel, End User, Product Type, Age Group - Global Forecast to 2030- Product Image
Sale

Carglumic Acid Market by Application, Distribution Channel, End User, Product Type, Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010728
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Carglumic Acid Market grew from USD 188.22 million in 2024 to USD 202.79 million in 2025. It is expected to continue growing at a CAGR of 7.45%, reaching USD 289.78 million by 2030.

Setting the Stage for Carglumic Acid Market Dynamics

The landscape of Carglumic Acid has transformed significantly as awareness of urea cycle disorders and related hyperammonemia conditions advances. Once confined to specialized metabolic centers, treatment regimens are now recognized as critical interventions in neonatal care and chronic disease management. An orphan drug by designation, Carglumic Acid addresses a vital unmet need by directly countering ammonia accumulation in patients with enzyme deficiencies. This medication’s mechanism of action-restoring the urea cycle’s function-has positioned it at the forefront of precision therapies for rare metabolic conditions.

In recent years, the confluence of heightened diagnostic capabilities and the expansion of newborn screening programs has driven early identification of affected individuals. Accordingly, healthcare providers are integrating Carglumic Acid protocols into neonatal intensive care units and long-term metabolic clinics. Alongside diagnostic advancements, evolving regulatory frameworks across major markets have facilitated accelerated approval pathways, underscoring the therapy’s clinical importance. As stakeholder engagement deepens-with clinicians, patient advocacy groups, and payers collaborating on value assessment-the commercial environment surrounding Carglumic Acid continues to mature into a more sophisticated, patient-centric ecosystem.

Unveiling the Forces Redefining the Treatment Landscape

A series of paradigm shifts is redefining the treatment landscape for rare metabolic disorders. Enhanced regulatory incentives, including orphan drug exclusivity extensions and priority review vouchers, have invigorated pipeline activity. Manufacturers are exploring novel formulations and combination regimens to improve bioavailability and patient adherence, while real-world evidence studies are strengthening value propositions through longitudinal outcome data.

Simultaneously, digital health innovations are reshaping care delivery. Telemedicine consultations enable metabolic specialists to support remote clinics, and connected health platforms monitor ammonia levels and dosing adherence in real time. This shift toward integrated, data-driven management is driving collaboration between pharmaceutical developers and digital solution providers to create holistic care ecosystems.

Meanwhile, the entrance of emerging biotechs and strategic partnerships is intensifying competition. Licensing agreements and co-development deals are accelerating global market entry, and geographic expansion strategies are targeting underserved regions. With these forces converging, industry participants must navigate a complex environment of regulatory variation, technological disruption, and shifting patient expectations to capture sustainable growth.

Assessing the Ripple Effects of US Tariffs in 2025

In early 2025, newly enacted United States tariffs on select pharmaceutical active ingredients have begun to reverberate through the supply chain, influencing production costs and pricing structures for Carglumic Acid. The levies, aimed at bolstering domestic manufacturing, have increased the landed cost of imported raw materials, prompting manufacturers to reassess sourcing strategies. Firms reliant on established API suppliers in Asia have encountered compressed margins, thereby accelerating efforts to qualify alternative domestic or nearshore sources.

These tariff-induced cost pressures have spurred manufacturers to optimize downstream operations. Contract development and manufacturing organizations are negotiating volume guarantees and exploring continuous manufacturing technologies to mitigate overhead. Payers, in turn, have heightened scrutiny on drug acquisition costs, intensifying reimbursement negotiations and value-based contracting discussions.

However, the evolving tariff regime also presents opportunities. Stakeholders investing in localized production capacity stand to benefit from reduced logistical complexities and enhanced supply resilience. As industry participants recalibrate their supply network footprints, the Carglumic Acid market may witness a strategic realignment that favors agility and cost transparency over traditional sourcing paradigms.

Deep Dive into Market Segmentation Nuances

The market’s multifaceted segmentation offers critical insights into adoption dynamics and growth drivers. Based on application, demand bifurcates between patients receiving therapy for secondary hyperammonemia due to acute liver dysfunction and those with inherited urea cycle disorders requiring lifelong treatment. Each group exhibits distinct clinical management patterns, influencing dosing regimens and support services.

Distribution channel analysis reveals that hospital pharmacies-both inpatient and outpatient-remain the primary access points for initial treatment initiation and acute dose administration. Concurrently, online pharmacies are gaining traction among caregivers seeking home delivery, while retail channels comprising chain and independent pharmacies cater to refill markets and community-based dispensing.

End user trends underscore the expanding role of home care providers in chronic management, as well as the continued reliance on specialty clinics where metabolic experts oversee treatment optimization. Large hospitals serve as referral hubs for complex cases, whereas small hospitals facilitate localized follow-up care. This end-user mosaic shapes service models and patient support frameworks.

From a product perspective, oral powder formulations dominate due to flexible dosing for neonates and pediatric patients, yet oral suspension options are increasingly preferred by adult patients and home care settings for ease of administration. Additionally, treatment protocols vary across age groups: neonates often require weight-based titration, pediatric patients benefit from tailored nutritional guidance, and adults prioritize regimen convenience.

Regional Pulse: Global Footprints and Growth Drivers

The Americas region continues to lead global uptake of Carglumic Acid, driven by robust newborn screening programs in the United States and Canada, comprehensive reimbursement frameworks, and established centers of excellence for rare metabolic diseases. High awareness among key opinion leaders and patient organizations fuels early diagnosis, while public and private payers increasingly recognize the long-term cost savings associated with preventing hyperammonemic crises.

In Europe, Middle East & Africa, regulatory alignment within the European Union has streamlined approval across multiple markets, although reimbursement timelines vary significantly by country. Patient advocacy initiatives in the Middle East are raising disease awareness and improving access, yet infrastructure gaps in certain African markets present persistent challenges. Strategic partnerships between global pharmaceutical companies and regional distributors are gradually improving market penetration.

Asia-Pacific exhibits significant growth potential as governments expand newborn screening mandates and introduce rare disease policies. Japan’s well-developed orphan drug framework and China’s progressive inclusion of metabolic therapies in public insurance schemes accelerate adoption, while India’s emerging market dynamics underscore the importance of cost-effective local production and patient assistance programs. Overall, regional diversity necessitates tailored market access strategies and stakeholder engagement plans.

Profiling the Vanguard: Leading Industry Players

A compact group of specialized pharmaceutical firms and contract service providers are shaping competitive dynamics in the Carglumic Acid market. Industry pioneers have secured orphan drug exclusivity, fostering a lead in branded formulations and reinforcing stakeholder trust through established safety and efficacy profiles. Concurrently, contract development and manufacturing organizations are expanding capabilities in high-potency API production, driving cost optimization and supply reliability.

Emerging biotech players are challenging incumbents by investing in next-generation delivery systems designed to improve stability and palatability, particularly for pediatric patients. These innovators are forging alliances with digital health companies to integrate remote monitoring tools, thereby enhancing real-world evidence generation and patient engagement.

In parallel, key strategic partnerships between global pharmaceutical firms and regional distributors are unlocking new channels in markets that have historically been underpenetrated. Such collaborations leverage local regulatory expertise and established distribution networks to accelerate launch timelines and streamline logistics.

Strategic Imperatives for Industry Leadership

To thrive in the evolving landscape, industry leaders must adopt a strategic focus on supply chain diversification, securing alternative API sources and investing in domestic manufacturing enhancements to offset tariff uncertainties. Prioritizing research and development for improved pediatric formulations will address critical patient needs and create differentiation in crowded markets.

Digital engagement initiatives should be elevated by partnering with telehealth platforms and patient support services, enabling real-time adherence monitoring and telephonic or virtual counseling. This approach not only enhances outcomes but also strengthens ties with payers through demonstrable value metrics.

Market access strategies must be refined through proactive value demonstration, leveraging real-world evidence and health economic models. Strengthening collaborations with patient advocacy groups and policymakers can expedite inclusion in reimbursement formularies and newborn screening programs. Finally, targeted geographic expansion into emerging markets should balance local manufacturing investments with risk-sharing agreements to ensure cost competitiveness and sustainable market presence.

Rigorous Framework Underpinning Our Analysis

This analysis rests on a dual methodological framework integrating comprehensive secondary research with in-depth primary data collection. Secondary sources encompassed peer-reviewed journals, regulatory agency databases, clinical trial registries, corporate filings, and healthcare policy documents, ensuring a robust foundation of published evidence. Primary insights were derived from structured interviews with metabolic disorder specialists, hospital pharmacists, patient advocacy leaders, and manufacturing executives, illuminating practical challenges and real-world perspectives.

Data triangulation was employed to validate findings against multiple inputs, while qualitative feedback from key opinion leaders informed nuanced interpretation of market dynamics. Coverage spanned all major regions, with market segmentation grounded in clinical application, distribution channels, end-user settings, product types, and age cohorts. Rigorous quality control protocols, including cross-checking of data tables and peer review by subject matter experts, underpin the credibility of conclusions and recommendations.

Synthesizing Insights for Forward Momentum

The Carglumic Acid market stands at a pivotal juncture, characterized by evolving policy landscapes, supply chain reshuffles, and a deeper understanding of patient heterogeneity. Strategic segmentation insights highlight the importance of tailoring distribution models and product formats to distinct clinical applications and end-user environments. Regional variations underscore the need for adaptive market access tactics that reconcile regulatory diversity with localized stakeholder priorities.

Leading companies are forging innovation pathways through formulation enhancements, digital health integration, and strategic alliances, yet the specter of tariff-driven cost pressures demands agile supply chain strategies. By harmonizing R&D investments with patient-centric service offerings and proactive engagement with payers and policymakers, firms can unlock new growth trajectories while reinforcing their reputations as committed partners in rare disease management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Secondary Hyperammonemia
    • Urea Cycle Disorders
  • Distribution Channel
    • Hospital Pharmacy
      • Inpatient Pharmacy
      • Outpatient Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Home Care
    • Hospitals
      • Large Hospitals
      • Small Hospitals
    • Specialty Clinics
  • Product Type
    • Oral Powder
    • Oral Suspension
  • Age Group
    • Adult
    • Neonate
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Ipsen S.A.
  • Marathon Pharmaceuticals, LLC
  • Recordati S.p.A
  • Jubilant Life Sciences Limited
  • Lonza Group AG
  • Cambrex Corporation
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Siegfried Holding AG
  • Fareva Group

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Carglumic Acid Market, by Application
8.1. Introduction
8.2. Secondary Hyperammonemia
8.3. Urea Cycle Disorders
9. Carglumic Acid Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Inpatient Pharmacy
9.2.2. Outpatient Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Carglumic Acid Market, by End User
10.1. Introduction
10.2. Home Care
10.3. Hospitals
10.3.1. Large Hospitals
10.3.2. Small Hospitals
10.4. Specialty Clinics
11. Carglumic Acid Market, by Product Type
11.1. Introduction
11.2. Oral Powder
11.3. Oral Suspension
12. Carglumic Acid Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Neonate
12.4. Pediatric
13. Americas Carglumic Acid Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Carglumic Acid Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Carglumic Acid Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Ipsen S.A.
16.3.2. Marathon Pharmaceuticals, LLC
16.3.3. Recordati S.p.A
16.3.4. Jubilant Life Sciences Limited
16.3.5. Lonza Group AG
16.3.6. Cambrex Corporation
16.3.7. Thermo Fisher Scientific Inc.
16.3.8. Recipharm AB
16.3.9. Siegfried Holding AG
16.3.10. Fareva Group
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CARGLUMIC ACID MARKET MULTI-CURRENCY
FIGURE 2. CARGLUMIC ACID MARKET MULTI-LANGUAGE
FIGURE 3. CARGLUMIC ACID MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CARGLUMIC ACID MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CARGLUMIC ACID MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CARGLUMIC ACID MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CARGLUMIC ACID MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CARGLUMIC ACID MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CARGLUMIC ACID MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CARGLUMIC ACID MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CARGLUMIC ACID MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARGLUMIC ACID MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CARGLUMIC ACID MARKET SIZE, BY SECONDARY HYPERAMMONEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARGLUMIC ACID MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARGLUMIC ACID MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARGLUMIC ACID MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARGLUMIC ACID MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARGLUMIC ACID MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARGLUMIC ACID MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARGLUMIC ACID MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARGLUMIC ACID MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARGLUMIC ACID MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARGLUMIC ACID MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARGLUMIC ACID MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CARGLUMIC ACID MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CARGLUMIC ACID MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CARGLUMIC ACID MARKET SIZE, BY NEONATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CARGLUMIC ACID MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CARGLUMIC ACID MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 54. CANADA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 55. CANADA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. CANADA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. CANADA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. MEXICO CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. GERMANY CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. GERMANY CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. GERMANY CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 103. GERMANY CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 104. GERMANY CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. GERMANY CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. GERMANY CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. FRANCE CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. FRANCE CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. FRANCE CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 111. FRANCE CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 112. FRANCE CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. FRANCE CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. ITALY CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. ITALY CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ITALY CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. ITALY CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 128. ITALY CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ITALY CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. ITALY CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. SPAIN CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. SPAIN CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SPAIN CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 135. SPAIN CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 136. SPAIN CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. SPAIN CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. DENMARK CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. DENMARK CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. DENMARK CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 167. DENMARK CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. DENMARK CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. QATAR CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. QATAR CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. QATAR CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 183. QATAR CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 184. QATAR CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. QATAR CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 186. QATAR CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. FINLAND CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. FINLAND CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. FINLAND CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 191. FINLAND CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. FINLAND CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. FINLAND CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. EGYPT CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. EGYPT CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. EGYPT CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 215. EGYPT CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 216. EGYPT CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. EGYPT CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 220. TURKEY CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. TURKEY CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. TURKEY CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 223. TURKEY CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. TURKEY CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. ISRAEL CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. NORWAY CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. NORWAY CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. NORWAY CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 239. NORWAY CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. NORWAY CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. NORWAY CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. POLAND CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. POLAND CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. POLAND CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 247. POLAND CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 248. POLAND CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. POLAND CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. POLAND CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. POLAND CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC CARGLUMIC ACID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 269. CHINA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. CHINA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. CHINA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. CHINA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 273. CHINA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. CHINA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. CHINA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. CHINA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. INDIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. INDIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. INDIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 280. INDIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 281. INDIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. INDIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 283. INDIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. INDIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. JAPAN CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. JAPAN CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. JAPAN CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 288. JAPAN CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 289. JAPAN CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. JAPAN CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 317. THAILAND CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 318. THAILAND CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. THAILAND CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 320. THAILAND CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 321. THAILAND CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. THAILAND CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 323. THAILAND CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 324. THAILAND CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 341. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 349. VIETNAM CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 350. VIETNAM CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 351. VIETNAM CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 352. VIETNAM CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 353. VIETNAM CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. VIETNAM CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 355. VIETNAM CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM CARGLUMIC ACID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 357. TAIWAN CARGLUMIC ACID MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 358. TAIWAN CARGLUMIC ACID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 359. TAIWAN CARGLUMIC ACID MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 360. TAIWAN CARGLUMIC ACID MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 361. TAIWAN CARGLUMIC ACID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 362. TAIWAN CARGLUMIC ACID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 363. TAIWAN CARGLUMIC ACID MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 364. TAIWAN CARGLUMIC ACID MARKET SIZE, BY AGE GROU

Companies Mentioned

The companies profiled in this Carglumic Acid market report include:
  • Ipsen S.A.
  • Marathon Pharmaceuticals, LLC
  • Recordati S.p.A
  • Jubilant Life Sciences Limited
  • Lonza Group AG
  • Cambrex Corporation
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Siegfried Holding AG
  • Fareva Group

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 202.79 Million
Forecasted Market Value ( USD ) by 2030 $ 289.78 Million
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Carglumic Acid - Global Strategic Business Report - Product Image

Carglumic Acid - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Amino Acid Metabolism Disorders Treatment Market by Treatment Type, Distribution Channel, End User, Product Type, Route of Administration, Patient Age Group - Global Forecast to 2030 - Product Image

Amino Acid Metabolism Disorders Treatment Market by Treatment Type, Distribution Channel, End User, Product Type, Route of Administration, Patient Age Group - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Phenylketonuria Treatment Market by Treatment Type, Route of Administration, Age Group, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Phenylketonuria Treatment Market by Treatment Type, Route of Administration, Age Group, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Phenylketonuria Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Phenylketonuria Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 260 Pages
  • Global
From
Postmenopausal Osteoporosis Treatment Market Size, Share & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Postmenopausal Osteoporosis Treatment Market Size, Share & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From

About the Market

Carglumic acid is a drug used to treat endocrine and metabolic disorders. It is a synthetic form of N-carbamoyl-L-glutamate, an intermediate in the urea cycle. Carglumic acid is used to treat N-acetylglutamate synthase (NAGS) deficiency, an inherited disorder that can cause ammonia to accumulate in the blood. It is also used to treat hyperammonemia, a condition in which the body has too much ammonia in the blood. Carglumic acid works by helping the body break down ammonia and other nitrogen-containing compounds. Carglumic acid is available in tablet and powder form. It is usually taken once or twice a day, depending on the condition being treated. Common side effects include nausea, vomiting, and diarrhea. The carglumic acid market is a niche market, with few companies offering the drug. Companies in the market include Orphan Europe, Orphan Technologies, and Orphan Canada. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.